Dr Joshua Solomon (National Jewish Health, Denver, CO, USA) kindly took the time to discuss the findings from the randomized, double-blinded, placebo-controlled TRAIL1 trial (NCT02808871) which investigated the safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease‘ (ABSTRACT NUMBER: L10) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- Could you tell us a little about rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its incidence, and unanswered questions in its treatment? (0:12)
- What were the aims and design of the TRAIL1 study? (0:53)
- What issues were experienced with recruitment? (1:26)
- What were the primary and secondary endpoints and how well were these achieved? (2:13)
- Which patients were most likely to respond to pirfenidone? (3:07)
Disclosures: Dr Joshua Solomon has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
